AIM ImmunoTech (AIM) said Wednesday its independent directors will now get 100% of their board compensation in the company's common shares instead of any director compensation in cash under a cash conservation plan devised by the compensation committee.
The company intends to attain important clinical benchmarks under the cash conservation plan, it added.
AIM said it will continue to disclose additional details about the conservation plan.
Shares of the company were down 1.8% in recent Wednesday trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.